| pubmed-article:18513974 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18513974 | lifeskim:mentions | umls-concept:C0003379 | lld:lifeskim |
| pubmed-article:18513974 | lifeskim:mentions | umls-concept:C0020235 | lld:lifeskim |
| pubmed-article:18513974 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:18513974 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:18513974 | lifeskim:mentions | umls-concept:C2742522 | lld:lifeskim |
| pubmed-article:18513974 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:18513974 | pubmed:dateCreated | 2008-6-13 | lld:pubmed |
| pubmed-article:18513974 | pubmed:abstractText | Cell cycle arrest of malignant cells is an important option for cancer treatment. In this study, we modified the structure of antimitotic 2-phenylindole-3-carbaldehydes by condensation with hydrazides of various benzoic and pyridine carboxylic acids. The resulting hydrazones inhibited the growth of MDA-MB 231 and MCF-7 breast cancer cells with IC(50) values of 20-30 nM for the most potent derivatives. These 2-phenylindole derivatives also exerted an inhibitory effect on the growth of both proliferating and resting U-373 MG glioblastoma cells. Though the hydrazones exhibited similar structure-activity relationships as the aldehydes, they did not inhibit tubulin polymerization as the aldehydes but were capable of blocking the cell cycle in G(2)/M phase. The cell cycle arrest was accompanied by apoptosis as demonstrated by the activation of caspase-3. Since these 2-phenylindole-based hydrazones display no structural similarity with other antitumor drugs they are interesting candidates for further development. | lld:pubmed |
| pubmed-article:18513974 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18513974 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18513974 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18513974 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18513974 | pubmed:issn | 1464-3391 | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:MüllerChristi... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:von... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:BednarskiPatr... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:KaufmannDoris... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:PojarováMicha... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:VogelSusanneS | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:PfallerTobias... | lld:pubmed |
| pubmed-article:18513974 | pubmed:author | pubmed-author:KühneSybilleS | lld:pubmed |
| pubmed-article:18513974 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18513974 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18513974 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:18513974 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18513974 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18513974 | pubmed:pagination | 6436-47 | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:meshHeading | pubmed-meshheading:18513974... | lld:pubmed |
| pubmed-article:18513974 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18513974 | pubmed:articleTitle | Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents. | lld:pubmed |
| pubmed-article:18513974 | pubmed:affiliation | Institut für Pharmazie, Universität Regensburg, D-93040 Regensburg, Germany. | lld:pubmed |
| pubmed-article:18513974 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18513974 | lld:chembl |
